Pharming Group N.V.

Board/Management Information • May 8, 2007

PHARMING PROPOSES NEW MEMBERS FOR SUPERVISORY BOARD

Leiden, The Netherlands, May 8, 2007. Biotech company Pharming Group NV ("Pharming" or "the Company") (Euronext: PHARM) announced today that it will propose two new members for its Supervisory Board at the upcoming Annual General Meeting of Shareholders on May 23, 2007. Pharming will propose to the Shareholders to appoint Messrs. J. Blaak and B. Ward to its Supervisory Board for a period of four years. At the same meeting, Mr. G. Verhagen will retire from his position as a Supervisory Director

Mr. Blaak (66), Dutch citizen, has an impressive track record in managerial positions with Hoogovens (and related companies) and Indivers (and subsidiary companies) in the Netherlands, USA, Germany and Singapore. In 1983, he was involved with the foundation of the MIP Equity Fund, one of the largest venture capital groups in Europe, and was appointed CEO in 1986. During the lifetime of the fund MIP invested in several life sciences companies that became active in The Netherlands (including Centocor, Mogen and EuroCetus/Chiron). Since 1996, Mr. Blaak is president and owner of Tailwind, a company investing in early stage life science companies. He is involved as a board member or advisor to several of these companies and also acts as a member of several advisory committees to the Dutch Ministry of Economic Affairs. Mr. Blaak studied physics, mathematics and business economics at the Free University of Amsterdam.

Dr. Ward (68), UK citizen, has a broad international network and experience in managing and financing biopharmaceutical companies. He has held senior management positions in the UK, USA and Singapore at several pharmaceutical and biotechnology companies, including Glaxo, the Virus Research Institute, Avant Immunotherapeutics and KuDOS Pharmaceuticals. His most recent position was CEO of KuDOS Pharmaceuticals Ltd., which was sold to Astra-Zeneca in 2006. He is currently chairman of Onyvax Ltd, Spirogen Ltd and Cellcentric Ltd. Dr. Ward is also a member of the board of Biotica Ltd and Cancer Research Technology Ltd. Dr. Ward holds a PhD in microbiology from the University of Bath (UK).

Mr. Ger Verhagen (77), who has served on Pharming's Supervisory Board since February 2002, has earlier indicated that he wishes to resign at the upcoming Annual General Meeting of Shareholders. The Board of Management, employees and Supervisory Board of Pharming are all very grateful to Mr. Verhagen, who has played a very important role in the growth of Pharming during the last five years. They respect his decision to reduce his professional activities and wish him all the best in many years to come.

The Annual General Meeting of Shareholders will be held on May 23, 2007 at 15:00 hrs at the offices of the Company in Leiden. The agenda with explanatory notes thereto (including data concerning the proposed new Members of the Supervisory Board, , proxy form,, the Annual Report including the report of the Board of Management and the financial results 2006 and route description are available for Shareholders at the offices of the Company as of today. Copies of these documents can be obtained free of charge and will also be available at the Company's website (www.pharming.com) as of today.

About Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, intermediates for various applications and nutritional products. Pharming has two products in late stage development - Rhucin® (recombinant human C1 inhibitor) for hereditary angioedema (MAA under review by EMEA) and human lactoferrin for use in food products (GRAS notification under review by US FDA). The advanced technologies of the Company include innovative platforms for the production of protein therapeutics and technology and processes for the purification and formulation of these products, as well as technologies in the field of tissue repair (via its collaboration with NovaThera) and DNA repair (via its acquisition of DNage BV). Additional information is available on the Pharming website, http://www.pharming.com and on http://www.dnage.nl.

This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements. The press release also appears in Dutch. In the event of any inconsistency, the English version will prevail over the Dutch version.

Contact:

Carina Hamaker Rein Strijker Investor Voice Pharming Group NV T: +31 (0)6 537 499 59 T: +31 (0)7 52 47 400 T: +31 (0)71 52 47 400